CN101507814B - 多组分抗原无细胞百日咳疫苗及其制备方法 - Google Patents
多组分抗原无细胞百日咳疫苗及其制备方法 Download PDFInfo
- Publication number
- CN101507814B CN101507814B CN2009100799831A CN200910079983A CN101507814B CN 101507814 B CN101507814 B CN 101507814B CN 2009100799831 A CN2009100799831 A CN 2009100799831A CN 200910079983 A CN200910079983 A CN 200910079983A CN 101507814 B CN101507814 B CN 101507814B
- Authority
- CN
- China
- Prior art keywords
- antigen
- vaccine
- multicomponent
- pertussis
- intracrine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000036639 antigens Human genes 0.000 title claims abstract description 276
- 108091007433 antigens Proteins 0.000 title claims abstract description 276
- 239000000427 antigen Substances 0.000 title claims abstract description 274
- 229940124832 acellular pertussis vaccine Drugs 0.000 title claims description 23
- 238000002360 preparation method Methods 0.000 title abstract description 46
- 229960005486 vaccine Drugs 0.000 claims abstract description 152
- 201000005702 Pertussis Diseases 0.000 claims abstract description 130
- 238000009630 liquid culture Methods 0.000 claims abstract description 65
- 238000005336 cracking Methods 0.000 claims abstract description 42
- 239000006228 supernatant Substances 0.000 claims abstract description 17
- 241000588832 Bordetella pertussis Species 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 95
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 86
- 210000001082 somatic cell Anatomy 0.000 claims description 55
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 41
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 39
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 28
- 229960000814 tetanus toxoid Drugs 0.000 claims description 28
- 239000012228 culture supernatant Substances 0.000 claims description 26
- 238000000746 purification Methods 0.000 claims description 25
- 239000000047 product Substances 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 230000000890 antigenic effect Effects 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 16
- 238000001556 precipitation Methods 0.000 claims description 15
- 239000002244 precipitate Substances 0.000 claims description 13
- 238000001784 detoxification Methods 0.000 claims description 12
- 229960003964 deoxycholic acid Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 101100446590 Arabidopsis thaliana FIM5 gene Proteins 0.000 claims description 5
- 101150106011 FIM2 gene Proteins 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- 239000004411 aluminium Substances 0.000 claims description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 3
- 108010049048 Cholera Toxin Proteins 0.000 claims description 3
- 102000009016 Cholera Toxin Human genes 0.000 claims description 3
- 239000003613 bile acid Substances 0.000 claims description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 241000606125 Bacteroides Species 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 108010012253 E coli heat-labile enterotoxin Proteins 0.000 claims description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 229940052491 bordetella pertussis Drugs 0.000 claims 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 1
- 229940066827 pertussis vaccine Drugs 0.000 abstract description 10
- 241001052560 Thallis Species 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 76
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 41
- 229960005323 phenoxyethanol Drugs 0.000 description 41
- 239000011780 sodium chloride Substances 0.000 description 38
- 229940032046 DTaP vaccine Drugs 0.000 description 33
- 230000004224 protection Effects 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000008215 water for injection Substances 0.000 description 20
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 18
- 238000012856 packing Methods 0.000 description 18
- 238000000855 fermentation Methods 0.000 description 11
- 230000004151 fermentation Effects 0.000 description 11
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 10
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 10
- 235000011130 ammonium sulphate Nutrition 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 10
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 10
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 238000000432 density-gradient centrifugation Methods 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000001641 gel filtration chromatography Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 229940024545 aluminum hydroxide Drugs 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 229960002668 sodium chloride Drugs 0.000 description 5
- 102000030621 adenylate cyclase Human genes 0.000 description 4
- 108060000200 adenylate cyclase Proteins 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000012297 crystallization seed Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 206010013023 diphtheria Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229940033663 thimerosal Drugs 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 101710145634 Antigen 1 Proteins 0.000 description 2
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960005097 diphtheria vaccines Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000011046 pyrogen test Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960002766 tetanus vaccines Drugs 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- APUIQTDTBPKWKE-RNPGEKFLSA-N (2r,6s)-6-[[(4r)-4-[[(2s)-2-[2-[[(1r,2s,3r,4r,5r)-4-acetamido-2-[(2s,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,8-dioxabicyclo[3.2.1]octan-3-yl]oxy]propanoylamino]propanoyl]amino]-4-carboxybutanoyl]amino]-2-amino-7-[[(2r)-2-am Chemical compound O([C@@H]1[C@H]2CO[C@H](O2)[C@H](NC(C)=O)[C@H]1OC(C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](CCC[C@@H](N)C(O)=O)C(=O)NC(=O)[C@H](N)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O APUIQTDTBPKWKE-RNPGEKFLSA-N 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229940032024 DPT vaccine Drugs 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000032754 Infant Death Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- -1 PT) Proteins 0.000 description 1
- 206010046861 Vaccination complication Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004784 molecular pathogenesis Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- Y02A50/472—
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100799831A CN101507814B (zh) | 2009-03-16 | 2009-03-16 | 多组分抗原无细胞百日咳疫苗及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100799831A CN101507814B (zh) | 2009-03-16 | 2009-03-16 | 多组分抗原无细胞百日咳疫苗及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101507814A CN101507814A (zh) | 2009-08-19 |
CN101507814B true CN101507814B (zh) | 2011-07-27 |
Family
ID=41000451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100799831A Active CN101507814B (zh) | 2009-03-16 | 2009-03-16 | 多组分抗原无细胞百日咳疫苗及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101507814B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102443572B (zh) * | 2011-10-21 | 2012-12-19 | 武汉生物制品研究所有限责任公司 | 一种对脱毒后的百日咳疫苗抗原溶液进行纯化的方法 |
CN102793915B (zh) * | 2012-07-25 | 2013-10-23 | 天津康希诺生物技术有限公司 | 一种无细胞百日咳疫苗的生产方法 |
CN108570098B (zh) * | 2017-12-29 | 2021-09-07 | 武汉生物制品研究所有限责任公司 | 一种百日咳多种抗原成分的分离纯化方法 |
CN109943536B (zh) * | 2019-03-26 | 2021-09-14 | 昆明理工大学 | 一种戊型肝炎病毒的培养方法及其灭活疫苗的制备方法 |
CN110358802B (zh) * | 2019-08-16 | 2021-06-18 | 长春百克生物科技股份公司 | 一种去除百日咳组分菌毛蛋白2/3内毒素的方法 |
CN111707822A (zh) * | 2020-08-20 | 2020-09-25 | 兆丰华生物科技(南京)有限公司 | 一种鸡毒支原体抗体检测试剂及制备方法和应用 |
CN114748616A (zh) * | 2022-05-23 | 2022-07-15 | 中国医学科学院医学生物学研究所 | 一种成人青少年用无细胞百白破联合疫苗及其制备方法 |
-
2009
- 2009-03-16 CN CN2009100799831A patent/CN101507814B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN101507814A (zh) | 2009-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101507814B (zh) | 多组分抗原无细胞百日咳疫苗及其制备方法 | |
RU2194531C2 (ru) | Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно (акдс)-полиомиелитные вакцины | |
CN103687612B (zh) | 无去污剂制备革兰氏阴性细菌外膜泡囊的方法 | |
CN101575593B (zh) | 手足口病疫苗及其制备方法和应用 | |
CN105007936A (zh) | 无细胞百日咳疫苗 | |
ES2560452T3 (es) | Vacuna de IPV-DPT | |
US20110262484A1 (en) | Outer membrane vesicle prime-protein boost vaccine | |
WO1979000823A1 (en) | Neisseria gonorrhoeae vaccine | |
CN103561763A (zh) | 免疫原性支气管炎博德特氏菌组合物 | |
CN106075423B (zh) | 一种预防手足口病的联合疫苗 | |
Hooke et al. | Live attenuated bacterial vaccines: new approaches for safety and efficacy | |
CN109395099B (zh) | 一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 | |
CN101524537B (zh) | 流感口服含片疫苗、流感口服缓释疫苗以及二者制备方法 | |
McDonnell et al. | Immunization | |
CN108619502A (zh) | 一种基于重组载体蛋白的季节流感-rsv-流脑联合疫苗 | |
CN107050446A (zh) | 经修饰的季节流感‑rsv联合疫苗及其制备方法 | |
Raw | Developing countries can innovate and produce vaccines: the case of Butantan in Brazil | |
CN1314449C (zh) | 乙型脑炎病毒疫苗和脑膜炎球菌结合疫苗组成的联合疫苗 | |
Gear | The South African poliomyelitis vaccine | |
JP2002525277A (ja) | Salmonellatyphiワクチン組成物 | |
JP3752264B2 (ja) | 混合ワクチン | |
Kassab | Development of Lipid Nanoparticles [LNP]-RNA Vaccine Against Neisseria Meningitidis CPS Gene Locus Facilitating the Synthesis of The Capsular Polysaccharide in Egypt | |
Sokefun et al. | Chronicles, Classes, Constituents, and Creation of Traditional Vaccines and COVID-19 Vaccines | |
US20040213806A1 (en) | Salmonella typhi vaccine compositions | |
CN1470286A (zh) | 一种增强免疫力的药物组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHENGDU ANTEJIN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: XUE PING Effective date: 20131203 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 101318 SHUNYI, BEIJING TO: 610041 CHENGDU, SICHUAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131203 Address after: 610041 No. 88 Park South Road, hi tech Zone, Sichuan, Chengdu Patentee after: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. Address before: 101318 Beijing Vanke City Garden 902 cloud Fengge Airport Industrial Zone Patentee before: Xue Ping |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Multi-component antigen acellular pertussis vaccine and preparation method thereof Effective date of registration: 20190110 Granted publication date: 20110727 Pledgee: Chengdu Tianfu International Biological City Investment and Development Co.,Ltd. Pledgor: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. Registration number: 2018510000127 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211116 Granted publication date: 20110727 Pledgee: Chengdu Tianfu International Biological City Investment and Development Co.,Ltd. Pledgor: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. Registration number: 2018510000127 |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: No.88 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610041 Patentee after: Fosun Antekin (Chengdu) Biopharmaceutical Co.,Ltd. Address before: No.88 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610041 Patentee before: CHENGDU ANTEJIN BIOTECHNOLOGY CO.,LTD. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Multicomponent antigen acellular pertussis vaccine and its preparation method Effective date of registration: 20230307 Granted publication date: 20110727 Pledgee: Industrial Bank Limited by Share Ltd. Chengdu branch Pledgor: Fosun Antekin (Chengdu) Biopharmaceutical Co.,Ltd. Registration number: Y2023510000063 |